Recently, alterations in GIPR expression have been reported in neuroendocrine tumors [39], neuroendocrine neoplasms [40], and medullary thyroid cancer [41], suggesting a clinically significant diagnostic and prognostic potential (for review see [33,34]). This evidence concerns the gene GIPR and medullary thyroid gland carcinoma.